Amneal Pharmaceuticals (AMRX) Total Liabilities (2018 - 2026)

Amneal Pharmaceuticals' Total Liabilities history runs 9 years deep, the most recent figure standing at $3.5 billion for Q1 2026.

• On a quarterly basis, Total Liabilities rose 5.2% year-over-year to $3.5 billion in Q1 2026; TTM through Mar 2026 was $3.5 billion, a 5.2% increase from a year earlier, with the FY2025 full-year figure at $3.7 billion, up 5.05% from the prior year.
• Total Liabilities fell to $3.5 billion in Q1 2026 per AMRX's latest filing, from $3.7 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $4.0 billion in Q2 2022 and bottomed at $3.4 billion in Q1 2025.
• The 5-year median for Total Liabilities is $3.6 billion (2025), against an average of $3.6 billion.
• Across the five-year window, Total Liabilities decreased 8.6% in 2023 and rose 5.2% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $3.8 billion in 2022, then declined by 8.6% to $3.5 billion in 2023, then rose by 0.83% to $3.5 billion in 2024, then increased by 5.05% to $3.7 billion in 2025, then dropped by 3.75% to $3.5 billion in 2026.
• Per Business Quant, the three latest AMRX Total Liabilities figures stand at $3.5 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.6 billion (Q3 2025).